Transcend Therapeutics, founded in 2021, is a clinical-stage, neuroscience-focused company developing rapid-acting treatments for neuropsychiatric diseases. Our mission is to develop new drugs for the millions of people for whom current psychiatric medicines have not worked. Our leadership team has made pivotal contributions to 13 FDA approvals (including recent MDD approval), $3.5B in M&A, and significant public company value creation. As a Public Benefit Corporation, we have pledged 10% of founding shares toward nonprofits focused on scientific research and access.
External link for Transcend Therapeutics
220 5th Ave
17
New York, NY 10001, US
Transcend Therapeutics reposted this
AlleyCorp portfolio companies raised nearly half a billion dollars in funding this quarter, but the most significant development was the compelling trial results of our incubation company, Transcend Therapeutics. Read more about it in our Q1 newsletter (link in comments below).
Today we announced positive top-line data from IMPACT-1, a randomized, double-blind, placebo-controlled, Phase 2 clinical trial evaluating TSND-201 (methylone), a rapid-acting neuroplastogen, for the treatment of PTSD. In addition to meeting the primary endpoint, the results demonstrate TSND-201’s potential as a rapid-acting and durable treatment for patients with PTSD. Learn more: https://lnkd.in/efbENMdA
Transcend Therapeutics reposted this
We need new and better treatments for PTSD. Millions of people suffer from PTSD, yet there are only two approved drugs and more than 60% of patients do not have a stable response to those medications. That’s why we’re pleased to share new clinical and preclinical data supporting our lead compound, TSDN-201, as a potential new treatment for PTSD. “This additional clinical and preclinical data gives us further confidence that TSND-201 could offer a rapid-acting, durable alternative to existing PTSD treatments for the 13 million Americans who suffer from PTSD,” said Transcend Therapeutics Co-Founder and CEO Blake Mandell. “We look forward to continuing to advance our ongoing Phase 2 trial of TSND-201 for PTSD and sharing results from the randomized, placebo-controlled portion of the trial in the second quarter of 2025.” #PTSD #mentalhealth https://lnkd.in/etATzze3
We need new and better treatments for PTSD. Millions of people suffer from PTSD, yet there are only two approved drugs and more than 60% of patients do not have a stable response to those medications. That’s why we’re pleased to share new clinical and preclinical data supporting our lead compound, TSDN-201, as a potential new treatment for PTSD. “This additional clinical and preclinical data gives us further confidence that TSND-201 could offer a rapid-acting, durable alternative to existing PTSD treatments for the 13 million Americans who suffer from PTSD,” said Transcend Therapeutics Co-Founder and CEO Blake Mandell. “We look forward to continuing to advance our ongoing Phase 2 trial of TSND-201 for PTSD and sharing results from the randomized, placebo-controlled portion of the trial in the second quarter of 2025.” #PTSD #mentalhealth https://lnkd.in/etATzze3
We’re excited to be at the American College of Neuropsychopharmacology annual meeting this week in Phoenix! We’ll be sharing the latest preclinical and clinical data for TSND-201 – our rapid-acting, neuroplastogen for PTSD. If you’re interested in learning more, stop by Posters W245 and W250 on Wednesday from 5-7pm. #ACNP2024 #PTSD https://lnkd.in/d-JPJA3
Our CEO and Co-Founder Blake Mandell recently spoke at the Fierce Biotech Summit about a revival in neurotherapeutics: "Many people are surprised to hear that there are currently five psychedelic drugs in Phase III trials with breakthrough designation from the FDA. These drugs are introducing a new paradigm in psychiatry, which is, why should a patient need to wait for weeks before knowing if the drug is working? Our belief is that patients want the rapid-acting treatment, but most would prefer a non-hallucinogenic experience. That's why we're so excited about the treatments we're developing at Transcend." You can listen to the full session by tuning into Fierce's "The Top Line" podcast. https://lnkd.in/eH3bSyss
We are thrilled to welcome Lily Eaker to the Transcend Therapeutics team as our new Senior Clinical Trial Associate! Lily joins us from Clario, where she was a Project Manager. She led the cardiac safety start-up, monitoring, and closeout phases for global clinical trials for a variety of biotech, pharmaceutical and CRO clients. Prior to this, Lily gained valuable experience as a Clinical Research Coordinator at the Mount Sinai Health System and as a Research Assistant at the New York State Psychiatric Institute, where she honed her skills in data management, study coordination, and regulatory compliance. She is a proud graduate of St. John’s University, where she earned a degree in Psychology. Welcome to the team, Lily! #welcome #newhire #clinicaltrialassociate #mentalhealth #Transcendtherapeutics
This week the Transcend team participated in the American Society for Clinical Psychopharmacology 2024 Annual Meeting. We were pleased to present three posters on TSND-201 (methylone), which demonstrated meaningful improvements in functioning and sleep-related symptoms in #PTSD patients. View our presentations here: https://lnkd.in/excSPsnp #IMPACT1 #theIMPACTprogram
We are thrilled to welcome Robert Barsic to the Transcend Therapeutics team as a Sr Clinical Trial Associate! Bobby joins us from Mount Sinai Health System, where he excelled as a Clinical Research Coordinator. During his time at Mount Sinai, Bobby was integral in managing clinical trials and ensuring regulatory compliance. Prior to his role at Mount Sinai, he gained valuable experience as a Medical Scribe at ScribeAmerica, where he assisted physicians with electronic medical records and patient encounters, developing a strong foundation in medical documentation and patient care. Bobby attended the College of the Holy Cross, where he worked as a research assistant in the Psychology Department. Welcome to Transcend, Bobby! #Welcome #NewHire #ClinicalTrialAssociate #TranscendTherapeutics #PTSD